Tazocin Intervention Study

Wyeth

Status and phase: Completed; Phase 4

Conditions: Bacterial Infections

Treatments: Drug: Tazocin (Piperacillin/Tazobactem)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00478855

0910X-102105

Details and patient eligibility

About

1. To determine the value of using piperacillin/tazobactam in reducing the cases of extended spectrum beta lactamases (ESBL) producing E. coli or K. pneumoniae colonization and infection.
2. To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre-and post-intervention in the selected medical centers.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• All patients admitted or transferred to the ICU/pulmonary/Infection units
• Patients of either sex, 18 years of age or older Patients who stay in units less than 48 hours will not be enrolled.

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)